\square

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject	to
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(b).	

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol KEMPHARM, INC [KMPH]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
<u>Tierney David S</u>			, <u></u> _ []	X	Director	10% Owner			
	(First) PHARM, INC.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/30/2019		Officer (give title below)	Other (specify below)			
1180 CELI	EBRATION BOU	LEVARD, SUITE 103	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line)	vidual or Joint/Group Filing (Check Applicab				
(Street)				X	Form filed by One Re	eporting Person			
CELEBRA	TION FL	34747			Form filed by More th Person	an One Reporting			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities / Disposed Of (5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
	Code V		v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(113(11.4)	
Common Stock	06/30/2019		Α		6,428(1)	Α	\$ <mark>0</mark>	19,372	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		5. Nut of Deriv Secut Acqu (A) or Dispo of (D) (Instr and 5	ative rities ired osed 3, 4	Expiration Date (Month/Day/Year)		Expiration Date Amount of			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			

Explanation of Responses:

1. Grant to the Reporting Person of a fully vested restricted stock award ("RSA") under the Issuer's 2014 Equity Incentive Plan. The RSA was granted to the Reporting Person in lieu of the quarterly cash compensation payable to the Reporting Person pursuant to the Issuer's Third Amended and Restated Non-Employee Director Compensation Policy.

<u>/s/ Timothy J. Sangiovanni,</u>	
Attorney-in-Fact for David S.	07/02/2019
<u>Tierney</u>	

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.